Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized observer-blind placebo-controlled study of GSK3888550A RSV maternal unadjuvanted vaccine in pregnant women and their infants
2019-001991-12Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing GSK3888550A RSVPreF3 vaccine with Placebo (2 arms). Primary endpoint: Solicited administration site events in maternal subjects. Started Oct 2019; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2019-001991-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001991-12.